Sun Pharmaceutical Industries’ one of the wholly owned subsidiaries has increased its shareholding in Ranbaxy Malaysia, Malaysia, by way of further purchase of 386,865 shares of face value of MYR 1.00 each (equivalent to 4.84%) of Ranbaxy Malaysia.
Ranbaxy Malaysia, is a subsidiary of the company, and the total shareholding of Sun Pharmaceutical Industries along with its wholly owned subsidiary is 85.90%, prior to this purchase of shares.
Post completion of this purchase of shares, the total holding of the company along with its wholly owned subsidiary will increase from 85.90% to 90.74% in Ranbaxy Malaysia.
Sun Pharmaceutical Industries is the world’s fourth largest specialty generic pharmaceutical company and India’s top pharmaceutical company.
Bhupendra Singh Chundawat is a seasoned technology journalist with over 22 years of experience in the media industry. He specializes in covering the global technology landscape, with a deep focus on manufacturing trends and the geopolitical impact on tech companies. Currently serving as the Editor at Udaipur Kiran, his insights are shaped by decades of hands-on reporting and editorial leadership in the fast-evolving world of technology.